Symbollon expands Iogen distribution
This article was originally published in The Tan Sheet
Executive Summary
New England Vitamin Brokers will expand the presence of Symbollon Pharmaceuticals Inc.'s Iogen women's breast health supplement in New England. Medfield, Mass.-based Symbollon said June 16 it is exploring additional retail distribution channels for Iogen, which launched in February touting clinically proven effects in women with fibrocystic breast disease (1"The Tan Sheet" Feb. 22, 2010). NEVB Director Michael Goolkasian called Iogen "a truly unique product supported by extensive clinical data.
You may also be interested in...
New Products In Brief
Symbollon takes supplement route: IoGen launches as a dietary supplement for women's breast health after Symbollon Pharmaceuticals' application with FDA seeking medical food approval stalled, said a spokeswoman for the Medfield, Mass., biotech firm. Symbollon completed eight clinical trials evaluating the effects of its molecular iodine compound on mastalgia and fibrosis in more than 2,000 patients. Starting in February, IoGen will be available in health food stores, online and through gynecologists, at a suggested retail price of $29.99 for 30 tablets
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.